Literature DB >> 24561031

Improving oncologic outcomes for women with endometrial cancer: realigning our sights.

Sean C Dowdy1.   

Abstract

This review will examine existing results on the postoperative treatment of women with high-risk and advanced stage endometrial cancer. Preliminary data suggests that response to treatment is highly dependent on both grade and stage. It is hoped that this discussion will highlight deficiencies in our collective knowledge base to be addressed in future clinical trials for the benefit of women with endometrial cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Endometrial cancer; Radiotherapy; Uterine serous carcinoma

Mesh：

Year:  2014        PMID： 24561031      PMCID： PMC4104975          DOI： 10.1016/j.ygyno.2014.02.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  26 in total

1.  Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer.

Authors:  S C Dowdy; B J Borah; J N Bakkum-Gamez; A L Weaver; M E McGree; L R Haas; G L Keeney; A Mariani; K C Podratz
Journal:  Gynecol Oncol       Date:  2012-07-03       Impact factor: 5.482

2.  Hematogenous dissemination in corpus cancer.

Authors:  A Mariani; M J Webb; G L Keeney; G Calori; K C Podratz
Journal:  Gynecol Oncol       Date:  2001-02       Impact factor: 5.482

3.  Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.

Authors:  Martin A Voss; Raji Ganesan; Linmarie Ludeman; Keith McCarthy; Robert Gornall; Gerhard Schaller; Wenbin Wei; Sudha Sundar
Journal:  Gynecol Oncol       Date:  2011-08-23       Impact factor: 5.482

4.  Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.

Authors:  Carien L Creutzberg; Remi A Nout; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan-Willem M Mens; Ludy C H W Lutgens; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

5.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

Authors:  Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen
Journal:  Eur J Cancer       Date:  2010-07-07       Impact factor: 9.162

6.  Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.

Authors:  Jamie N Bakkum-Gamez; Andrea Mariani; Sean C Dowdy; Amy L Weaver; Michaela E McGree; Janice R Martin; Gary L Keeney; Aminah Jatoi; Bobbie S Gostout; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

7.  Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.

Authors:  Tina A Ayeni; Jamie N Bakkum-Gamez; Andrea Mariani; Michaela E McGree; Amy L Weaver; Michael G Haddock; Gary L Keeney; Harry J Long; Sean C Dowdy; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2013-03-25       Impact factor: 5.482

8.  Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

Authors:  Kaled M Alektiar; Andrea McKee; Oscar Lin; Ennapadam Venkatraman; Michael J Zelefsky; Brady McKee; William J Hoskins; Richard R Barakat
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

9.  Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study.

Authors:  D Boll; H E Karim-Kos; R H A Verhoeven; C W Burger; J W Coebergh; L V van de Poll-Franse; H C van Doorn
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2012-11-22       Impact factor: 2.435

10.  A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

Authors:  Angeles Alvarez Secord; Melissa A Geller; Gloria Broadwater; Robert Holloway; Kevin Shuler; Nhu-Y Dao; Paola A Gehrig; David M O'Malley; Neil Finkler; Laura J Havrilesky
Journal:  Gynecol Oncol       Date:  2012-10-17       Impact factor: 5.482
View more
  14 in total

1.  T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.

Authors:  Shiho Asaka; Ting-Tai Yen; Tian-Li Wang; Ie-Ming Shih; Stephanie Gaillard
Journal:  Mod Pathol       Date:  2018-11-06       Impact factor: 7.842

Review 2.  The mutational landscape of endometrial cancer.

Authors:  Bo Hong; Matthieu Le Gallo; Daphne W Bell
Journal:  Curr Opin Genet Dev       Date:  2015-01-23       Impact factor: 5.578

Review 3.  Immune check-point in endometrial cancer.

Authors:  Francesca De Felice; Claudia Marchetti; Vincenzo Tombolini; P Benedetti Panici
Journal:  Int J Clin Oncol       Date:  2019-05-02       Impact factor: 3.402

4.  Sentinel Lymph Node Mapping in Endometrial Cancer: An Update.

Authors:  Fady Khoury-Collado; Caryn St Clair; Nadeem R Abu-Rustum
Journal:  Oncologist       Date:  2016-03-09

5.  Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.

Authors:  Xiao-Hui Zhang; Pin Hu; Yang-Qin Xie; Yong-Jun Kang; Min Li
Journal:  Mol Cell Biol       Date:  2019-11-12       Impact factor: 4.272

6.  Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer.

Authors:  Hiroshi Matsushima; Taisuke Mori; Fumitake Ito; Takuro Yamamoto; Makoto Akiyama; Tetsuya Kokabu; Kaori Yoriki; Shiori Umemura; Kyoko Akashi; Jo Kitawaki
Journal:  Oncotarget       Date:  2016-06-07

7.  Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).

Authors:  Jen-Ruei Chen; Ting-Chang Chang; Hung-Chun Fu; Hei-Yu Lau; I-Hui Chen; Yu-Min Ke; Yu-Ling Liang; An-Jen Chiang; Chia-Yen Huang; Yu-Chieh Chen; Mun-Kun Hong; Yu-Chi Wang; Kuo-Feng Huang; Sheng-Mou Hsiao; Peng-Hui Wang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.

Authors:  Tommaso Cornali; Paolo Sammartino; Nikolaos Kopanakis; Athina Christopoulou; Marialuisa Framarino Dei Malatesta; Elias Efstathiou; Alessandra Spagnoli; Antonio Ciardi; Daniele Biacchi; John Spiliotis
Journal:  Ann Surg Oncol       Date:  2017-12-27       Impact factor: 5.344

9.  Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.

Authors:  Rainer Kimmig; Antonella Iannaccone; Bahriye Aktas; Paul Buderath; Martin Heubner
Journal:  Arch Gynecol Obstet       Date:  2015-11-23       Impact factor: 2.344

10.  Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?

Authors:  Chiachien Jake Wang; Alana Christie; Michael R Folkert; Xian Jin Xie; Kevin Albuquerque
Journal:  J Gynecol Oncol       Date:  2018-03-06       Impact factor: 4.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.